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Abstract
The genetic etiology of intellectual disability remains elusive in almost half of all affected individuals. Within the Solve-RD
consortium, systematic re-analysis of whole exome sequencing (WES) data from unresolved cases with (syndromic)
intellectual disability (n= 1,472 probands) was performed. This re-analysis included variant calling of mitochondrial DNA
(mtDNA) variants, although mtDNA is not specifically targeted in WES. We identified a functionally relevant mtDNA
variant in MT-TL1 (NC_012920.1:m.3291T > C; NC_012920.1:n.62T > C), at a heteroplasmy level of 22% in whole blood,
in a 23-year-old male with severe intellectual disability, epilepsy, episodic headaches with emesis, spastic tetraparesis, brain
abnormalities, and feeding difficulties. Targeted validation in blood and urine supported pathogenicity, with heteroplasmy
levels of 23% and 58% in index, and 4% and 17% in mother, respectively. Interestingly, not all phenotypic
features observed in the index have been previously linked to this MT-TL1 variant, suggesting either broadening of the
m.3291T > C-associated phenotype, or presence of a co-occurring disorder. Hence, our case highlights the importance of
underappreciated mtDNA variants identifiable from WES data, especially for cases with atypical mitochondrial phenotypes
and their relatives in the maternal line.
Introduction
The introduction of whole exome sequencing (WES) in
clinical settings has massively augmented diagnostic yield for
intellectual disability (ID) and other neurodevelopmental
disorders (NDD), and additionally identified many new
disease-gene associations. Yet, ~50–70% of individuals with
ID/NDD remain undiagnosed [1]. The Solve-RD project [2]
systematically reanalyzes exomes and phenotypic data of
19,000 unsolved cases with rare disease from four European
Reference Networks (ERNs) to elucidate the genetic etiol-
ogy, including ~5,000 cases from ERN-ITHACA (Intellec-
tual Disability, TeleHealth and Congenital Anomalies;
https://ern-ithaca.eu/). Exploration of mitochondrial DNA
sequences extracted from WES data is part of this effort [3],
as 27 of the 37 mitochondrial genes have a known disease-
gene association (http://www.mitomap.org).
MT-TL1 encodes mitochondrial tRNALeu(UUR), involved
in the synthesis of oxidative phosphorylation enzymes by
adding leucine to the growing polypeptide chain of mtDNA-
encoded subunits during translation [4]. Pathogenic variants
in MT-TL1 have been linked to several phenotypes
associated with mitochondrial dysfunction [5], including
mitochondrial myopathy, encephalopathy, lactic acidosis
and stroke-like episodes (MELAS; MIM#540000) and
myoclonic epilepsy associated with ragged-red fibers
(MERRF; MIM#545000).
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We report on a variant in MT-TL1 known to interfere
with mitochondrial function, uncovered by systematic re-
analysis of WES data, illustrating the underexposed
potential of WES-based analysis of mtDNA in identifying
variants with clinical consequences.
Methods
Patient inclusion
All individuals (or legal representatives) in the Solve-RD
project provided consent, compliant with local ethical
guidelines and the Declaration of Helsinki. For this case, the
Radboudumc Ethics Board approved the study (2018-
4986). For publication of photos, additional consent was
obtained.
WES
Diagnostic trio-based exome sequencing (proband and
parents) was performed as described previously [6] using
DNA isolated from whole blood.
Data sharing
Human Phenotype Ontology-coded clinical data were
uploaded along with BAM files to the RD-Connect Gen-
ome-Phenome Analysis Platform (https://platform.rd-
connect.eu/), and deposited at European Genome-
Phenome Archive (EGAZ00001527897), as part of
the Solve-RD infrastructure [2]. The variant and phenotype
were submitted to the Leiden Open Variation Database
(individual number 00328346, phenotype number
0000246573, variant number 0000713909).
Variant identification
Systematic re-analysis of WES data is described by
Matalonga et al. [3]. Details specific to this case include
mapping, calling, and annotation of mtDNA using
MToolBox pipeline (version 1.0) [7], with mapping against
rCRS (for mtDNA) and GRCh37/Hg19 (for genomic DNA)
as reference sequences, allowing the detection of hetero-
plasmy levels and prioritization of variants. The following
parameters were applied to identify possible disease-
associated variants: (1) coverage ≥8-fold; (2) heteroplasmy
fraction ≥1%; (3) GeneBank allele frequency (MITOMAP)
<0.2%; (4) “Confirmed” or “Reported” disease association
in MITOMAP; and (5) reported “Pathogenic” (ACMG,
class 5) or “Likely pathogenic” (ACMG, class 4) in
ClinVar.
Heteroplasmy validation
Confirmation of mitochondrial heteroplasmy was performed
on blood and urine of the proband, mother and sisters using




We report on a 23-year-old male proband with a complex
neurodevelopmental and neuromuscular phenotype, who
remained undiagnosed despite extensive diagnostic eva-
luation in a tertiary center. Family history was unremark-
able, with two healthy older sisters and non-consanguineous
parents. After uncomplicated pregnancy and delivery at
term (normal birth weight (3840 g) and length (52 cm); head
circumference 34 cm, 0 SD; Apgar score 10), first concerns
about development arose around 3 months of age. At age
15 months, there was severe developmental delay, consist-
ing of hypotonia, delayed motor, social and communicative
milestones, and secondary microcephaly (44 cm, −2.5 SD).
Brain MRI (at 15 months; repeated at age 14 years) showed
supratentorial pachygyria and frontoparietal polymicrogyria
(Fig. 1A), with white matter abnormalities in the posterior
limb of the internal capsule (Fig. 1B). Cerebellum and
corpus callosum showed no deformities and EEG did not
show epileptiform activity at age 15 months.
He developed spastic tetraparesis, orofacial dystonia,
and dystonia of hands and feet. Epilepsy manifested at 7
years of age with frontal focal-onset seizures, with and
without secondary tonic-clonic generalization. No myo-
clonus was observed. Deterioration occurred at age 17
with episodes of severe headaches, accompanied by
nausea, vomiting, hematemesis, pallor and perspiration,
coinciding with epileptiform activity on EEG in the left
temporal lobe. Brain CT was interpreted as normal at that
time (Fig. 1C). Different anti-epileptic drugs were pre-
scribed, of which several resulted in adverse drug reac-
tions including erythema multiforme (carbamazepine,
oxcarbazepine), muscle weakness (clobazam, pregabalin),
or obstructive sleep apnea syndrome (clobazam), resol-
ving after cessation of the respective medication. Because
of poor seizure control, 24-h continuous EEG monitoring
was performed at 18 years and showed bilateral inde-
pendent and simultaneous periodic discharges, which
were more frequent during sleep than during wakefulness.
He is now largely seizure free on low-dose carbamaze-
pine. Other medical problems were severe progressive
neuromuscular scoliosis (Fig. 2A), bilateral hip dysplasia
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Fig. 1 Neuroimaging displays pachygyria, polymicrogyria, white
matter abnormalities, and loss of gray–white differentiation. Cor-
onal MRI images (A) in the phase-sensitive inversion recovery
sequence at age 14 years. The images in the upper row show
exemplary regions with a microgyrated aspect (red arrow) as compared
to the contralateral region (blue arrow). The images in the lower row
show exemplary regions with pachygyration (red arrow). In these
regions, the gyrus–sulcus pattern is lost as compared to the con-
tralateral side (blue arrow). Polymicrogyria and pachygyria appear
most prominent in the frontoparietal cortical areas. Axial T2-weighted
MR images (B; left) and fluid attenuation inversion recovery (FLAIR)
images (B; right) at the level of basal ganglia at age 14 years. The
middle row shows a magnification of the basal ganglia derived from
images in the upper row, with a schematic representation in the lower
row. 1: caudate nucleus; 2: putamen; 3: globus pallidus; 4: thalamus;
dotted line: white matter in between the basal ganglia representing the
area of the internal capsule. In the posterior limb of the internal cap-
sule, white hyperintensities are present. These can be recognized by
their T2-weighted/FLAIR hyperintense aspect and suggest micro-
structural white matter degeneration. In addition, the globus pallidus
on both sides shows a hypo-intense aspect on the T2-weighted images
and FLAIR sequence. Axial CT scan images (C) in brain tissue setting
(W/L: 90/40 HU) at age 17 years. Slides should be viewed from left to
right to follow the caudocranial axis; the upper-left corner shows the
most caudal slide, the lower-right corner shows the most cranial slide.
The red circles indicate the hypodense configuration of the temporal
lobe with loss of gray–white differentiation. Gray–white differentia-
tion refers to the appearance of the interface between cerebral white
matter and cerebral gray matter on brain CT imaging. Loss of
gray–white differentiation often indicates the occurrence of cytotoxic
edema. In turn, cytotoxic edema is typical for infarction and hypoxic-
ischemic encephalopathic syndromes. A clear asymmetry between the
left temporal lobe and the right temporal lobe can be observed. The
hypodense configuration involves the superior, middle, and inferior
temporal gyri (Color figure online).
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with luxation, drooling with excessive tenacious stringy
mucus, and severe feeding difficulties requiring gastric
tube feeding and resulting in low body weight (age 18:
length 165 cm, −2.6 SD; weight 39.5 kg, weight-for-
length −3.1 SD; head circumference 54 cm, −1.9 SD).
Ophthalmological assessment, visual and brainstem
13 year 19 year
6 year









1362 E. de Boer et al.
auditory evoked potentials, and electrocardiography were
normal. Facial dysmorphisms at 19 years of age included
a long hypotonic face, full eyebrows, long palpebral fis-
sures, a prominent nose and nasal bridge, high palate,
gingival hyperplasia, and abnormal tooth implant
(Fig. 2B–D), becoming more prominent over time
(Fig. 2E).
Karyotype, genomic micro-array (Agilent 180k oligo-
array), targeted analysis of WDR62 and ADGRG1, extensive
lysosomal screening, and trio-based WES did not yield a
diagnosis. Metabolic workup revealed elevation of multiple
amino acids, including glycine, serine, threonine (in plasma
and urine), lysine, methionine, and alanine (in plasma), in a
pattern not described for a known metabolic disorder. Lactate
in blood (1.8 mmol/l, age 20 years) and cerebrospinal fluid
(1.0 mmol/l, age 15 months) were within normal range.
Pharmacogenetic analysis showed a rare homozygous variant
in CYP3A4 (NM_017460.5:c.878T > C;*18; rs28371759)
unlikely to explain the largely dose-independent adverse drug
reactions, and two rare HLA-types (HLA-A*0103; HLA-
B*0835) of unknown significance.
Systematic re-analysis revealed a known pathogenic
variant in MT-TL1
Data of the proband and parents were included in the Solve-RD
project. Prioritization of nuclear DNA variants did not yield
diagnostically relevant variants, despite analysis of (de novo)
variants in known disease–genes, particularly those associated
with recessive or dominant cortical dysplasia, and in genes not
yet implicated in NDD/ID. Variant prioritization from mtDNA
revealed a variant in MT-TL1 [8], NC_012920.1:m.3291T >C
(NC_012920.1:n.62T >C), known to affect mitochondrial
function, at 22% heteroplasmy. The variant was absent from
maternal WES data.
Validation was performed on blood of the proband and
his mother using routine diagnostic procedures, displaying a
heteroplasmy level of 23% in the index, compared to 4% in
his mother. Urine heteroplasmy levels were 58% and 17%
in index and mother, respectively. Follow-up of the family
revealed heteroplasmy levels of 4% (blood) and 9% (urine)
in one of the sisters, but the variant was absent from blood
and urine of the other sister. We re-evaluated brain CT
imaging of the index, performed at age 17 years, which in
retrospect showed early signs of stroke, including loss of
gray–white differentiation in the left temporal lobe
(Fig. 1C), co-localizing with epileptiform activity seen on
EEG at the time of onset of episodic symptoms. Addition-
ally, multidisciplinary evaluation and comparison of his
phenotype to previously published individuals with the
same variant (Table 1) revealed that the proband exhibits
several symptoms seen in other individuals (epilepsy, epi-
sodic headaches with emesis, feeding difficulties, low body
weight, and neuromuscular problems) [9–14], but also
features that were not described before (abnormalities of
brain gyration, facial dysmorphisms, early age of onset of
developmental delay).
Discussion
Systematic re-analysis of existing WES data of unresolved
cohorts can efficiently yield additional diagnoses [15]. Yet,
re-analysis rarely includes evaluation of mtDNA although
pathogenic mtDNA variants underly many rare diseases.
This case illustrates the importance of including mtDNA in
re-analysis, as the identification of the MT-TL1 variant is of
medical relevance to the proband and his sisters of
childbearing age.
Mitochondrial disorders associated with mitochondrial
tRNA genes are characterized by both genotypic and
phenotypic heterogeneity, with poor genotype–phenotype
correlations [8, 16, 17]. The m.3291T > C variant descri-
bed here is located in the T-loop of mitochondrial
tRNALeu(UUR). This variant was shown to result in
respiratory chain enzyme deficiency and its pathogenicity
was proven by single muscle fiber mtDNA analysis,
showing high heteroplasmy levels in cytochrome c oxi-
dase deficient muscle fibers [8]. Individuals carrying the
m.3291T > C variant display a broad phenotypic spectrum
varying from mild symptoms to severely debilitating
disease [8–14, 18, 19], largely overlapping with features
observed in the index. As no additional diagnostically
relevant variants could be identified, it remains unclear
whether the early age of onset of developmental delay,
gyration defects, and dysmorphisms are attributable to a
second rare genetic disorder, or expand the m.3291T > C
phenotypic spectrum. However, despite gyration defects
Fig. 2 Clinical and radiology images show severe scoliosis, dys-
morphisms, and dental crowding. A Clinical photographs without
traction (left) and with traction (middle) showing asymmetry of the
chest and rib protrusion on the left side. Radiograph of the vertebral
column (right) with anteroposterior view in supine position shows a
slight left convex curvature of the upper thoracic spine and severe right
convex scoliosis of thoracolumbar spine (Cobb’s angle ±75°) with
axial rotation (asymmetric projection of spinous processes and pedi-
cles) and asymmetry of the thoracic cavity. B Frontal and C profile
facial photographs of the proband (age 19 years), showing a long face
with hypotonic appearance, long palpebral fissures, a prominent nose,
and small simple ears. The photograph of the mouth (D) shows
crowded teeth with gingival hyperplasia (age 21 years). Facial pho-
tographs between age 5 months and age 23 years (E), showing a
progression of facial dysmorphisms with advancing age. Only mild
dysmorphic features are observed in early childhood, including ptosis
and a long philtrum (age 5 months to 4 years). However, the proband
develops a progressively pronounced long hypotonic face with open
mouth (e.g., photographs at 19 versus 10 versus 2 years of age), and
has crowded teeth at age 21 (D), whereas teeth appear less crowded at
earlier ages (age 7, 13, and 17 years).
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being uncommon in individuals with MT-TL1 variants,
polymicrogyria has been reported for m.3243A > G in two
unrelated individuals with atypical MELAS pheno-
types, additionally exhibiting other atypical symptoms
also observed in the proband, including hypertonia, early
onset developmental delay [20, 21] and facial dys-
morphisms [20]. The proband’s facial dysmorphisms
might be secondary to muscle tone abnormalities. Hence,
we concluded that the MT-TL1 variant could at least in
part, but possibly completely, explain the proband’s
phenotype.
In conclusion, we describe a male proband carrying a
mtDNA variant confirmed to interfere with mitochondrial
function, that was identified in systematic, large-scale re-
analysis on a large cohort of individuals with unresolved
(syndromic) ID through the collaborative Solve-RD project.
Our observations suggest that re-analysis encompassing the
mtDNA interpreted from WES data may successfully yield
novel unanticipated diagnoses in unexplained cases of
ERN-ITHACA with implications for reproductive choices
of relatives in the maternal line.
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